NCT06612671

Brief Summary

Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 9, 2023

Completed
22 days until next milestone

Study Start

First participant enrolled

October 1, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 25, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

September 25, 2024

Status Verified

September 1, 2024

Enrollment Period

9 months

First QC Date

September 9, 2023

Last Update Submit

September 22, 2024

Conditions

Retroperitoneal Sarcoma

Keywords

Retroperitoneal SarcomaSurgeryRadiotherapy

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    After treatment, patients will undergo long-term follow-up to record their survival status.

    The proportion of patients still alive at 1 year, 3 years, and 5 years after treatment.

Secondary Outcomes (1)

  • Progression free survival

    The rates of local recurrence, regional recurrence, or distant metastasis at 1 year, 3 years, and 5 years after treatment.

Other Outcomes (2)

  • The resectability of preoperative embolization

    From the start of preoperative evaluations to the day of surgery, it typically spans 7 days.

  • The value of eGFR in renal function

    Period from date before surgery to the date one year after suregry

Interventions

tumor wide excisionPROCEDURE

patients received properative or post-operative radiotherapy

Also known as: Radiation

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital. The preoperative procedure including angiography or TAE, radiotherapy is allowed.

You may qualify if:

  • the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital

You may not qualify if:

  • the patient did not receive complete tumor excision in our hospital
  • the pathological report yielded not malignancy tumor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taichung Veterans General Hospital

Taichung, Taiwan

Location

MeSH Terms

Interventions

Radiation

Intervention Hierarchy (Ancestors)

Physical Phenomena

Study Officials

  • Radiation-Oncology Department Liu, M.D.

    Department of Radiation-Oncology, Taichung Veterans General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2023

First Posted

September 25, 2024

Study Start

October 1, 2023

Primary Completion

July 1, 2024

Study Completion

September 30, 2025

Last Updated

September 25, 2024

Record last verified: 2024-09

Locations

TW(1)